Andarix Pharmaceuticals Information

Andarix Pharmaceuticals is a clinical stage company developing targeted imaging and therapies for lung, neuroendocrine, and other cancers based on a proprietary somatostatin peptide conjugate. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung cancers. Lung cancer is the leading cause of cancer mortality in the United States for both men and women. In 2013, there were an estimated 225,470 new diagnoses of non-small cell lung cancer (NSCLC) with 42,000 small cell lung cancer patients.